tiprankstipranks
Trending News
More News >
CryoPort Inc (CYRX)
NASDAQ:CYRX
US Market
Advertisement

CryoPort (CYRX) Earnings Dates, Call Summary & Reports

Compare
636 Followers

Earnings Data

Report Date
Nov 06, 2025
After Close (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
-0.22
Last Year’s EPS
-0.02
Same Quarter Last Year
Based on 8 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Aug 05, 2025|
% Change Since: 12.17%|
Earnings Call Sentiment|Positive
Cryoport's earnings call highlighted strong revenue growth, strategic partnerships, and expanding service offerings, suggesting a positive trajectory. However, challenges such as a temporary client distribution pause, regulatory setbacks, and stagnant growth in China present notable obstacles. Despite these challenges, the overall sentiment remains optimistic due to the company's strategic initiatives and market positioning.
Company Guidance -
Q3 2025
In the second quarter of 2025, Cryoport reported significant financial growth across its Life Sciences Services, with service revenue increasing by 21% year-over-year and accounting for 54% of total revenue from continuing operations. This was driven by a 33% increase in revenue from commercial cell and gene therapies and a 28% growth in BioStorage/BioServices. Additionally, Life Sciences products saw an 8% year-over-year revenue growth. The company achieved a 14% overall increase in total revenue from operations and improved gross margins, alongside a meaningful rise in adjusted EBITDA. Cryoport reaffirmed its full-year 2025 revenue guidance, bolstered by the completion of a strategic partnership with DHL Group, which included a $200 million cash infusion from the sale of CRYOPDP. This partnership is expected to enhance their global biologics capabilities, particularly in the Asia Pacific (APAC) and Europe, Middle East, and Africa (EMEA) regions.
Strong Double-Digit Revenue Growth
Cryoport reported a 14% overall increase in total revenue from operations, with service revenue growing by 21% year-over-year, accounting for 54% of total revenue from continuing operations.
Commercial Cell and Gene Therapies Revenue Surge
Revenue from commercial cell and gene therapies increased by 33%, highlighting the rising demand for Cryoport's integrated temperature control supply chain platform.
BioStorage/BioServices Growth
BioStorage/BioServices revenue grew by 28%, indicating strong demand for Cryoport's storage and service offerings.
Successful Strategic Partnership with DHL
A strategic partnership with DHL Group was launched, resulting in approximately $200 million in cash payments to Cryoport, enhancing global biologics capabilities and positioning Cryoport for expansion in Asia Pac and EMEA.
Continued Clinical Trial Support
Cryoport supported a record 728 clinical trials, approximately 70% of industry cell and gene therapy trials, with expectations for additional application filings and therapy approvals.
MVE Product Line Expansion
An 8% year-over-year revenue growth was reported in Life Sciences products, driven by demand from animal health customers and the launch of new vapor shippers and cryogenic storage systems.

CryoPort (CYRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CYRX Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Nov 06, 2025
2025 (Q3)
-0.22 / -
-0.02
Aug 05, 2025
2025 (Q2)
-0.26 / 2.05
-1.62226.54% (+3.67)
May 07, 2025
2025 (Q1)
-0.34 / -0.28
-0.4334.88% (+0.15)
Mar 04, 2025
2024 (Q4)
-0.29 / -0.42
-1.3167.94% (+0.89)
Nov 07, 2024
2024 (Q3)
-0.31 / -0.02
-0.3193.55% (+0.29)
Aug 06, 2024
2024 (Q2)
-0.40 / -1.62
-0.42-285.71% (-1.20)
May 07, 2024
2024 (Q1)
-0.34 / -0.43
-0.16-168.75% (-0.27)
Mar 12, 2024
2023 (Q4)
-0.28 / -1.31
-0.24-445.83% (-1.07)
Nov 08, 2023
2023 (Q3)
-0.32 / -0.31
-0.15-106.67% (-0.16)
Aug 09, 2023
2023 (Q2)
-0.24 / -0.42
-0.23-82.61% (-0.19)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

CYRX Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Aug 05, 2025
$6.74$8.75+29.82%
May 07, 2025
$5.66$6.98+23.32%
Mar 04, 2025
$5.06$6.61+30.63%
Nov 07, 2024
$8.02$7.73-3.62%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does CryoPort Inc (CYRX) report earnings?
CryoPort Inc (CYRX) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).
    What is CryoPort Inc (CYRX) earnings time?
    CryoPort Inc (CYRX) earnings time is at Nov 06, 2025, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is CYRX EPS forecast?
          CYRX EPS forecast for the fiscal quarter 2025 (Q3) is -0.22.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis